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Objectives: To study the potential factors include gene mutation, efﬂux pump and alteration
of  permeability associated with quinolone-resistance of Salmonella enterica strains isolated
from  patients with acute gastroenteritis and to evaluate the degree of synergistic activity of
efﬂux pump inhibitors when combined with ciproﬂoxacin against resistant isolates.
Methods: Antimicrobial resistance patterns of ﬁfty-eight Salmonella isolates were tested. Five
isolates were selected to study the mechanism of resistance associated with quinolone
group,  including mutation in topoisomerase-encoding gene, altered cell permeability, and
expression of an active efﬂux system. In addition, the combination between antibiotics and
efﬂux  pump inhibitors to overcome the microbial resistance was evaluated.
Results:  Five Salmonella isolates totally resistant to all quinolones were  studied. All isolates
showed  alterations in outer membrane proteins including disappearance of some or all of
these proteins (Omp-A, Omp-C, Omp-D and Omp-F). Minimum inhibitory concentration val-
ues of ciproﬂoxacin were determined in the presence/absence of the efﬂux pump inhibitors:
carbonyl  cyanide m-chlorophenylhydrazone, norepinephrin and trimethoprim. Minimum
inhibitory  concentration values for two of the isolates were 2–4 fold lower with the addition
of  efﬂux pump inhibitors. All ﬁve Salmonella isolates were ampliﬁed for gyrA and parC genes
and  only two isolates were sequenced. S. Enteritidis 22 had double mutations at codon 83 and
87  in addition to three mutations at parC at codons 67, 76 and 80 whereas S. Typhimurium
57  had three mutations at codons 83, 87 and 119, but no mutations at parC.mp Conclusions:  Efﬂux pusystems  which are the m
negative  clinical isolates.
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Introduction
Salmonella enterica is a bacterial pathogen that causes a variety
of  diseases in humans, including gastroenteritis, bacteremia,
and  typhoid fever.1 Antimicrobial agents are not usually
used  for the treatment of salmonellosis but can be life-
saving  in case of severe or systemic infection.2 Quinolones
and  ﬂuoroquinolones are broad spectrum antibacterial agents
commonly  used in both clinical and veterinary medicine. They
are  a group of synthetic antimicrobial agents with excellent
activity  against Enterobacteriaceae. However, the number of
quinolone-resistant isolates has increased in recent years and
such  resistance can counteract the efﬁcacy of antimicrobial
therapy.3,4 The global increase in the prevalence of Salmonella
strains  with reduced susceptibility to quinolones constitutes
a  major concern, since these pathogens have been associated
with  a signiﬁcant burden of hospitalization and mortality and
with  clinical failures of therapy.5–7
Quinolone resistance in Gram-negative pathogens is usu-
ally  acquired by chromosomal mutations, primarily in the
quinolone  resistance-determining regions (QRDRs) of the tar-
get genes, gyrA and gyrB, which encode DNA gyrase, and parC
and  parE, which encode topoisomerase IV.8 Quinolones act by
inhibiting the action of type II topoisomerases, DNA gyrase
and  topoisomerase IV.9 Resistance can also be acquired by
minimizing  the accumulation of the antimicrobial agent in the
cell  by either one or both of the following mechanisms: altered
expression  of porins leading to decreased penetration of ﬂuo-
roquinolones  within bacteria or increased efﬂux of quinolones
from  the bacterial cell due to overexpression of the AcrAB-TolC
efﬂux  pump that acts synergistically with the outer membrane
mutation.3,10
Efﬂux pumps that contribute to resistance to many  classes
of  antimicrobial agents, including ﬂuoroquinolones, have
been  described in a number of clinically important bacteria
such  as Salmonella, Escherichia coli, Pseudomonas aeruginosa and
others.2 Pumps may  be speciﬁc for one substrate or may  trans-
port  a range of structurally dissimilar compounds (including
antibiotics of multiple classes); such pumps can be associ-
ated  with multiple drug resistance (MDR). In the prokaryotic
kingdom there are ﬁve major families of efﬂux transporter.2,11
Most of the multidrug transporters belonging to the RND fam-
ily  interact with a membrane fusion protein (MFP) and an
outer  membrane protein (OMP) to allow drug transport across
both  the inner and the outer membranes of Gram-negative
bacteria.12 The RND efﬂux pump AcrAB-TolC in Enterobac-
teriaceae and homologues thereof in other Gram-negative
bacteria is the system most commonly associated with innate
and  acquired chromosomally mediated MDR. Clinical isolates
that  overexpress efﬂux pumps usually overproduce this pump
and  there is an association of MDR  mediated by efﬂux with
prior  use of ﬂuoroquinolones.4 Due to the lack of new antibac-
terial  agents, there is considerable interest in restoring the
activity  of older antimicrobial compounds. One way  to do
this  is to inhibit the action of MDR  efﬂux pumps that con-
fer  innate resistance to these older agents; this is an area of
active  drug development by pharmaceutical companies.13 In
order to overcome resistance due to overexpressions of efﬂux
pump,  efﬂux pump inhibitors (EPIs) were  used by different 1 3;1  7(4):431–437
functions,4 some of these EPIs affect antibiotic efﬂux not by
inhibiting  the pump but rather by competing favorably with
the  antibiotic for extrusion.14
The goal of this study was to determine the resistance
mechanism to ﬂuoroquinolones in Salmonella isolates and
investigate  the association of quinolone resistance with muta-
tions  in the genes encoding for DNA gyrase and topoisomerase
IV  of S. enterica, with the study of quinolones efﬂux from the
bacterial  cell and permeability alteration. In addition, to study
the  use of efﬂux pump inhibitors to increase the accumulation
of  ﬂuoroquinolones in Salmonella.
Materials  and  methods
Bacterial  isolates
The bacterial strains used in this study were collected from
Clinical  Microbiological Laboratory of three hospitals in Cairo,
Egypt  along a period of eighteen months (from July 2008
through December 2009). One hundred isolates were  obtained
from  a culture of either blood or stool from individual patients
with  acute gastroenteritis. Salmonella isolates were  selected
using  standard selective and differentiated media, biochem-
ical  tests, and serological test based on standard criteria. S.
enterica  serovar Typhimurium ATCC 14028 was  used as a ref-
erence  strain.
Antibacterial  susceptibility  testing
Antimicrobial resistance patterns of ﬁfty-eight (58) Salmonella
isolates  selected out of 100 samples were tested, using differ-
ent  antimicrobial agents, by the agar disk diffusion method.
Bacteria  were  grown until they reached a ﬁnal inoculum
of  5 × 105 CFU/mL as compared to 0.5 McFarland standard
then streaked on Mueller-Hinton agar (Difco). Used antimi-
crobial  disks (g/disc) (Oxoid, UK) included ampicillin (AMP,
10  g), oxacillin (OX, 1 g), cefotaxime (CTX, 30 g), ceftazi-
dine (CAZ, 30 g), ceﬁpime (FEP, 30 g), amoxicillin/clavulinic
acid (AMC, 30 g), as -lactam group; levoﬂoxacin (LEV, 5 g),
oﬂoxacin  (OFX, 5 g), norﬂoxacin (NOR, 30 g), ciproﬂoxacin
(CIP, 5 g) and nalidixic acid (NA, 30 g) as ﬂuoroquinolones
group and streptomycin (S, 10 g), gentamycin (GN, 10 g) and
amikacin  (AK, 30 g) as aminoglycosides group. Plates were
incubated  at 37 ◦C for 24 h. Salmonella isolates were  deﬁned as
sensitive,  intermediate or resistant based on the size of the
inhibition  zone according to breakpoints established by CLSI
documents.15
Preparation  and  analysis  of  outer  membrane  proteins
(OMPs)
Five multidrug resistant, especially to ﬂuoroquinolones group,
clinical  isolates of S. enterica were selected for genetic study.
Outer  membrane protein was  obtained from an exponen-
tial  phase culture as described by Miró et al.16 Bacteria were
◦separated by centrifugation (5000 × g, 4 C, 15 min) and were
subsequently sonicated. Cell envelopes were  recovered by
centrifugation (5000 × g, 4 ◦C, 15 min) and treated with lau-
rylsarcosynate (Sigma). OMPs were obtained by means of
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Table 1 – Oligonucleotide primers used for ampliﬁcation
of  QRDR for the RAPD PCR assay and sequencing of gyrA
and  parC genes.
Primer Primer (5′–3′) Amplicon size Length
gyrA
Fw CGTTGGTGACGTAATCGGT
251 bp 70–152
Rv  CCGTACCGTCATAGTTATC
parC
Fw CTATGCGATG TCAGAGCTGG
270  bp 47–133
Rv  TAACAGCAGCTCGGCGTATTb r a z j i n f e c t d i s .
n additional centrifugation step (13,000 × g, 4 ◦C, 60 min).
MPs  extracts were  solubilized in sample buffer (ﬁnal con-
entration:  10 mg/mL) submitted to sodium dodecyl sulphate
olyacrylamide gel electrophoresis (SDS-PAGE) and stained
sing  Comassie blue, then the proteins band analyzed using
el  Pro Analyzer V. 3.0 to determine the molecular weights and
mount  of protein bands.
etection  of  active  efﬂux  pump  systems
 variety of methods has been used to identify active efﬂux
ystems  in bacteria, such as ﬂuorometric assays or the deter-
ination  of the minimum inhibitory concentration (MIC) for
uoroquinolones group in the presence of compounds known
o  modulate the activity of efﬂux pumps (as efﬂux pump
nhibitors, EPIs)
The  Ethidium Bromide-agar Cartwheel (EtBrCW) method
roved  to be a valuable tool for the rapid and simple screening
f  efﬂux pump activity,17 for ﬁve clinical isolates of selected
DR  S. enterica. Brieﬂy, each culture was  swabbed onto TSA
lates  containing EtBr concentrations ranging from 0.1 to
.5  mg/L (0.1 mg/L increments). The plates were incubated at
7 ◦C for 16 h, after which the minimum concentration of EtBr
ssociated  with the bacterial mass that produced ﬂuorescence
nder  UV light using transilluminator of 312 nm (Model LMS-
0E,  USA) was  determined.
To  assess the activity of AcrAB efﬂux pumps, minimal
nhibitory concentrations (MICs) of ciproﬂoxacin were per-
ormed  by microtiter plate method alone and in the presence
f  different putative efﬂux pump inhibitors (EPIs): carbonyl
yanide  m-chlorophenylhydrazone (CCCP), norepinephrine
NOR) and trimethoprim (TMP) (Sigma, St. Louis, USA). MICs
t  concentrations ranging from 0.125 to 512 g/mL were deter-
ined  for ﬁve selected Salmonella isolates. All antibiotics and
fﬂux  pump inhibitors were used according to the manufac-
urer’s  instructions.
etection  of  target  gene  mutations
ive clinical isolates of S. enterica were used to obtain in vitro
QR  and two of them were  selected for detection of target
ene  mutation. Polymerase chain reaction (PCR) ampliﬁcation
as  carried out to detect the presence of gyrase and Topo
V  enzymes in Salmonella. DNA sequencing detects mutations
n  the quinolone resistance determining regions (QRDRs) of
he  gyrA and parC genes. Ampliﬁcation was  carried out using
APD-PCR  cycling program in thermal cyclers (Techne-TC-512
TC-100:M). The primers (Sigma–Aldrich, USA) were designed
ccording  to Eaves et al.,18,19 and were used for PCR ampliﬁ-
ation and sequencing as listed in Table 1 which includes all
ases  previously detected as mutation hot spots.
PCR products were extracted and puriﬁed using DNA
el  extraction kit (Montage, Millipore) and sequencing was
erformed  by Jena Gen GmbH Biotechnologie-Gentechnik-
iagnostik (Jena, Germany) using the BigDyeTM Cycle
equencing Kit (Applied Biosystems, Weiterstadt, Germany)
n  a 3130 sequencer (Applied Biosystems).
The results were  analyzed using Bioedit software version
.0  where the nucleotides of gyrA and parC from QRDR wereFw, forward; Rv, reversible; bp, base pair.
compared to nucleotides of Salmonella isolates in GenBank
accession nos. X78977 and AE008878, respectively.
Results
Fifty-eight (58%) out of the 100 isolates collected from the three
hospitals  were  identiﬁed by microscopic examination, selec-
tive  and differential media, biochemical tests and serological
test  as S. enterica. Out of the 58% Salmonella isolates, 41.3% rep-
resented  S. Typhimurium, 27.58% S. Enteritidis, 5.17% S. Typhi,
3.44%  both S. Paratyphi A and B, and 18.96% other Salmonella.
All  Salmonella isolates were assayed for resistance to antibac-
terial  agents of three groups. Only ﬁve (8.62%) among the
tested  strains appeared to be totally resistant to all antibacte-
rial  agents of the quinolone and ﬂuoroquinolone groups and
to  most of the agents of the two other groups (Table 2). The ﬁve
resistant  isolates were S. enterica serovar Typhimurium num-
ber  7, 54 and 57 (S-7, S-54 and S-57) and S. enterica serovar
Enteritidis number 22 (S-22) and S. Typhi number 49 (S-49).
In  the present study OMP expression was altered in the
ﬁve  multidrug resistant Salmonella isolates, based on elec-
trophoretic mobility (Table 3), and the reference strain S.
Typhimurium ATCC 14028 had OmpA, OmpC, OmpD and
OmpF.  Expression of Omp-F was lost in all isolates except
in  S. Typhimurium (S-7), while OmpD was expressed in S.
Typhimurium (S-57) only. The isolates S. Typhimurium (S-54)
and  S. Entreritidis (S-22) did not show the major non-speciﬁc
outer membrane proteins. Quinolone MIC for the former iso-
late  was  higher than for the other four isolates. Salmonella
Typhi (S-49) had lower quinolone MIC  than the four other iso-
lates  (Table 3); it had two bands corresponding to OmpA and
OmpC.  Also, the major non-speciﬁc outer membrane protein
with  the molecular weight of 49 kDa was detected in all mul-
tidrug  resistant Salmonella isolates.
The application of EtBrCW method allowed for the selec-
tion  of two EtBrCW-positive (isolates S-22 and S-57) isolates,
whereas  the remaining three isolates were considered to have
no  or intermediate efﬂux activity. Based upon these results,
we  continued the study by further analyzing the two EtBrCW-
positive  isolates.
Three  compounds of efﬂux pump inhibitors (EPI) were  used
to  decrease the MICCIP by two different mechanisms: car-
bonyl  cyanide m-chlorophenylhydrazone (CCCP) (inhibition of
proton-motive force driven efﬂux pumps),21,22 norepinephrine
(NOR) and trimethoprim(TMP) (inhibits speciﬁc RND efﬂux
pumps)  and is known to be active against the AcrAB-TolC
434  b r a z j i n f e c t d i s . 2 0 1 3;1  7(4):431–437
Table 2 – Antimicrobial susceptibility of selected ﬁve multidrug resistant Salmonella isolates according to CLSI (2012).
Antibiotics Salmonella  isolates
S. Tm 7 S. En 22 S. Ty 49 S. Tm 54 S .Tm 57
Aminoglycosides
Streptomycin (S) R S R R R
Gentamycin (GN) R R R R R
Amikacin (AK) R R R R I
ˇ-Lactams
Ampicillin (AMP) R  R R R R
Amoxicillin/clavulanic acid (AMC) R R R R R
Oxacillin (OX) R R R R R
Cefotaxime (CTX) R R I R R
Ceftazidine (CAZ) R R S R S
Ceﬁpime (FEP) R R R R R
Quinolones and ﬂuoroquinolones
Ciproﬂoxacin  (CIP) R R R R R
Levoﬂoxacin (LEV) R R R R R
Oﬂoxacin (OFX) R R R R R
Norﬂoxacin (NOR) R R R R I
Nalidixic acid (NA) R R R R R
Susceptible, intermediate and resistant phenotypes, from CLSI breakpoints.
Table 3 – Major OMP  of ﬁve multidrug resistant Salmonella isolates.
Isolate no. Serovar MICs (g/mL) Protein content (g/mL)
OmpA OmpC OmpD OmpF
Sensitive strain S. Typhimurium ATCC 14028 – 6.52 5.35 5.22 6.64
S-7 S. Typhimurium 64 – – – 3.16
S-22 S. Enteritidis 256 – – – –
S-49 S. Typhi 32 2.23 2.89 – –
S-54 S. Typhimurium >512 – – – –
S-57 S. Typhimurium 512 – – 1.51 –
ein.MIC, minimum inhibitory concentration; Omp, outer membrane prot
transporters.4 MICCIP determined in absence of EPIs were  com-
pared  with those determined in presence of efﬂux inhibitors.
The  results showed twofold or more  reduction in MIC levels
(Table  4) for the two multidrug resistant Salmonella isolates
(EtBrCW-positive isolates) tested.
Table 4 – MICs values of different EPIs used against quinolone r
characterization of QRDR region of gyrA and parC gene.
Isolate no. Serovar QRDR mutation
gyrA 
S22 S. Enteritidis Ser83Phe
Asp87Ser
Se
A
C
S57 S. Typhimurium Ser83Phe
Asp87Gly
Ala119Ser
N
Amino acids: serine (Ser), phenylalanine (Phe), aspartic acid (Asp), glyc
(CIP), carbonyl cyanide m-chlorophenylhydrazone (CCCP), norepinephrine
resistance determining region (QRDR).
Numbers in parenthesis represent the numbers of fold decrease.As ciproﬂoxacin is a substrate of many  efﬂux pumps
in  different bacterial species,23 the study focused upon
usage of compounds that displayed synergistic activity with
ciproﬂoxacin. So the use of the EPIs like CCCP, trimethoprim
and norepinephrine in combination with antibiotic revealed
esistant Salmonella isolates and molecular
MICs  (g/mL)
CIP
parC NO
EPI
+
CCCP
+
NOR
+
TMP
r67Cys
rg76Cys
ys80Arg
256  32 (−3) 64 (−2) 16 (−4)
o mutation 512 128 (−2) 32 (−4) 64 (−3)
ine (Gly), arginine (Arg), alanine (Ala), cysteine (Cys), ciproﬂoxacin
 (NOR), trimethoprim (TMP), efﬂux pump inhibitor (EPI), quinolone
b r a z j i n f e c t d i s . 2 0 1 3;1 7(4):431–437  435
M 1 2 3 4 5 +ve M 1 2 3 4 5 +ve
251 pb
276 pb
Fig. 1 – QRDR ampliﬁcation of gyrA (251 bp) and parC (276 bp) from DNA of ﬁve Salmonella isolates.
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tynergistic antibacterial activity for improving and potentiat-
ng  the activity of antibiotics.
The  mechanism of resistance to ﬂuoroquinolones is caused
y  mutations in a region of the gyrA gene resulting in amino
cid  changes between amino acid positions 67 and 106. This
egion  has been termed the quinolone resistance-determining
egion (QRDR). The QRDR of gyrA (251 bp) and parC (276 bp) was
mpliﬁed  for the ﬁve multidrug resistant Salmonella isolates as
epresented in Fig. 1 to detect the presence of these genes and
onﬁrm  the identiﬁcation of the ﬁve Salmonella isolates.
The  QRDR of the genes gyrA and parC of two selected QR
almonella isolates (S22 and S57) were  tested for mutations by
NA ampliﬁcation and sequencing. Results revealed that S.
nteritidis (S-22) and S. Typhimurium (S-57) contained dou-
le  mutation at codon 83 (Ser83-Phe) and codon 87 (Asp87-Ser
n  S22 or Gly in S57). One novel mutation was detected in S.
yphimurium (S-57) inside QRDR, Ala-119, in which G-T led
o  the substitution of alanine to serine (Ala119-Ser); while
n  S. Enteritidis (22) there is seven mutations within QRDR
rom  codon (115–122) and other mutations outside QRDR. The
51-nucletide  fragment of gyrA and 270 nucleotide fragment
f  parC that were  ampliﬁed from the quinolone-resistant S.
yphimurium (S-57) and S. Enteritidis (S-22) had over 70% and
0%  identity with the same fragment from the reference strain
X78977)  and reference strain (AE008878), respectively. Other
utations  found in different positions did not seem to have
linical  signiﬁcance.
iscussion
he occurrence of antibiotic-resistant bacteria of all genera
ncreased  recently. The scientiﬁc community should, there-
ore,  perform routine surveillance of microbial population
o  determine the extent of antibiotic resistance in order to
rovide  suitable treatment guidelines.
Davin-Regli et al. and O’Regan et al. found that the loss
f  one OMPs or the decrease in its amount compared with
he  parent strain cause a high resistance rate in Salmonella
25,26solates. This was  also seen here in the ﬁve tested
almonella isolates. Miró et al. discussed the relevance of pro-
ein  losses to resistance to -lactams and quinolones, stating
hat  the expression of the other porin presumably allows forsufﬁcient  penetration of antimicrobial agents to inhibit the
microorganism as shown in Klebsiella pneumoniae and E. coli.16
Ruiz et al. stated that analysis of OMPs and lipopolysac-
charides from quinolone-susceptible and quinolone-resistant
clinical isolates showed no porin changes.27 Hamid and Jain
reported  that isolates which contain the non-speciﬁc outer
membrane  protein with the molecular weight of 49 KDa may
be  used as a vaccine for protection against typhoid.28
Efﬂux pumps are transport proteins involved in the extru-
sion  of toxic substrates (including virtually all classes of
clinically  relevant antibiotics) from within cells into the exter-
nal  environment.29 Efﬂux activity was assessed by means of a
fast and practical test, the Ethidium Bromide-agar Cartwheel
(EtBrCW), which provides information on the capacity of each
isolate  to extrude EtBr from the cells by efﬂux, on the basis
of  the ﬂuorescence emitted by cultures swabbed in EtBr-
containing agar plates.
The  outer membrane modiﬁcation acts synergistically with
enhanced  active efﬂux systems to affect the level of the intrin-
sic  and the acquired antibiotic resistance of Gram-negative
bacteria as stated by Nikaido.30 The smallest concentration of
EtBr  that produces ﬂuorescence of the bacterial mass repre-
sents  the highest concentration of EtBr that the bacteria can
extrude,  consequently producing ﬂuorescence is signiﬁcantly
greater.  The concentration of EtBr needed to produce ﬂuores-
cence  of the bacterial mass is considerably higher than that
concentration which produces ﬂuorescence of the wild-type
strain.31
Several chemical families of EPIs have now been described
and  characterized.20 Among them several inhibitor com-
pounds display an efﬁcient activity and inhibit the major
AcrAB-TolC in Salmonella efﬂux systems which are the major
efﬂux  pumps responsible for MDR Gram-negative clinical
isolates.  The NOR and TMP have structure analog as phenyl-
arginine--naphthylamide (PAN). PAN is routinely used in
the  laboratory as a screen to indicate efﬂux-mediated antibi-
otic  resistance in Gram-negative bacteria. However, PAN is
not  used in the clinical setting due to toxicity and bioavail-
ability issues, but NOR and TMP are already licensed for use
in  man.4,32The twofold or greater reduction in MIC  levels obtained
here for the two multidrug resistant Salmonella isolates
conﬁrm the presence of an active efﬂux component in
those  isolates.4,33 Piddock et al.4 found the MIC  values of
i s . 2 0
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ciproﬂoxacin to be 2–4 fold reduced in the presence of
trimethoprim for wild-type strains of Salmonella Typhimurium
and  NCTC type strains of Enterobacter cloacae, Serratia
marcescens, P. aeruginosa, K. pneumoniae and E. coli. However,
no  synergy was  seen between trimethoprim and ciproﬂoxacin
for  strains of Salmonella Typhimurium in which acrA, acrB,
acrAB  or tolC were  inactivated. Also Keddy et al. found that
in  the presence of EPIs, the MIC  of ciproﬂoxacin decreased by
twofold,  and the MIC of nalidixic acid decreased by ﬁvefold,
establishing the involvement of an efﬂux pump in conferring
quinolone resistance.34 TMP  and NOR were the most effective
inhibitors in reducing MIC  values. While CCCP showed less
effect  on MIC  values for the compounds tested, this result pro-
vided  evidence for an active efﬂux process that uses the proton
motive  force as energy source.21,22 However, no full reversion
of  the ciproﬂoxacin resistance phenotype was  obtained with
any  of the EPIs tested, suggesting the contribution of other
mechanisms to this resistance, namely, mutations in the tar-
get genes.
The main mechanism of resistance to ﬂuoroquinolones in
Gram-negative bacteria is caused by mutations in genes cod-
ing  for DNA-gyrase (gyrA and gyrB) and topoisomerase IV (parC
and parE).24 Results of the test for mutations, by DNA ampli-
ﬁcation  and sequencing the QRDR of the genes gyrA and parC
of  two selected QR Salmonella isolates (S22 and S57) agree with
those  of Guerra et al.,35 Marimón et al.,33 and Chen et al.2
Griggs et al. suggested that other mutations could be present
in  the gyrA genes of these isolates, outside of the region of the
sequenced  gene, and that the Ala119 mutation is not involved
in  quinolone resistance.36 Eaves et al. found novel mutations
inside QRDR at codon Asp72, Asp82 and Ala119 and also out-
side  the QRDR, but within the ampliﬁed region of DNA.18
Amino acid changes at Ser-83 (to Phe, Tyr or Ala) or at Asp-
87  (to Gly, Asn or Tyr) are the most frequently observed in
nalidixic  acid-resistant strains.37 Double mutations at both
residues  83 and 87 have been identiﬁed in clinical isolates
of  S. Typhimurium DT204 showing high-level resistance to
ﬂuoroquinolones.35 Nonetheless, O’Regan et al. stated that
there  is a single gyrA mutation (D87Y) present in all strains
showing  high-level nalidixic acid resistance.26 Hirose et al.39
and Dimitrove et al.38 demonstrated that single point muta-
tion  in QRDR of gyrA led to decreased susceptibility to
ciproﬂoxacin in Salmonella isolates. There is also three amino
acid  substitution in parC at codon Ser67-Cys, Arg76-Cys and
Cys80-Arg  in S. Enteritidis (S-22), in agreement with results
obtained  by Choi et al. and Wu et al.40,41 However, in S.
Typhimurium S-57 and the in wild strains no amino acid muta-
tion  in parC gene has been reported. It is unlikely that this
mutation  contributes to quinolone resistance. This indicates
that  this substitution is likely to be a polymorphism not com-
mon  in resistant strains of Salmonella.
Obtained data showed that S. Typhimurium (S-57) has high
MICCIP with mutations in only gyrA, while S. Entridies (S-
22)  has lower MICCIP with mutation in gyrA and parC. These
results  clearly suggest that parC mutations are not neces-
sary  to generate high level resistance to ciproﬂoxacin. In this
19respect  Eaves et al. found that isolates with a mutation in
both  gyrA and parC were  more  susceptible to ciproﬂoxacin
than were isolates with a mutation in gyrA alone. Previous
studies42 have demonstrated that changes in topoisomerases 1 3;1  7(4):431–437
are insufﬁcient to explain the level of resistance to quinolones
in  S. enterica. In agreement with this observation, Miró et al.16
showed that multiple resistance mechanisms were  involved
in  the strains including changes in topoisomerases, altered
permeability, and expression of an active efﬂux. Our results
showed  that multiple resistance mechanisms were  involved
in  the strains including changes in topoisomerases, as shown
in  double mutation at both codons 83 and 87 in gene gyrA and
mutation  inside QRDR in both isolates and three mutations in
parC only in S. Enteritidis, altered permeability, and expression
of  an active efﬂux.
Conclusion
The data obtained in this work strongly suggest the impor-
tance  of mutations in gyrase and topoisomerase in quinolone
resistance development in Salmonella, although other fac-
tors  such as overexpression of efﬂux pumps can play a
complementary role. Additionally, our study underscores the
importance  of using EPI (NOR and TMP) to inhibit the major
AcrAB-TolC in Salmonella efﬂux systems which are the major
efﬂux  pumps responsible for MDR Gram-negative clinical
isolates. MDR and ﬂuoroquinolone-resistance in Salmonella
recovered from patients are common in Egypt, and monitoring
antimicrobial resistance of foodborne pathogens should be an
important component of the surveillance system to improve
public  health.
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